Exploring molecular targets in diabetic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic kidney disease (DKD) is the primary cause of end-stage kidney disease, posing a significant clinical challenge.
• The precise mechanisms driving DKD progression, including glomerular hyperfiltration, oxidative stress, inflammation, hypoxia, and epigenetics, are not fully elucidated.
• Currently, no definitive treatment exists for DKD, necessitating the exploration of novel therapeutic strategies.

Purpose of the Study:

• To review current and emerging therapeutic approaches for diabetic kidney disease.
• To highlight novel drug targets and agents being investigated for DKD treatment.
• To discuss the potential of new therapies in managing DKD and improving patient outcomes.

Main Methods:

• Review of clinical trials and preclinical studies on DKD treatments.
• Analysis of pharmacological agents targeting specific pathways involved in DKD.
• Examination of emerging therapeutic candidates and their mechanisms of action.

Main Results:

• Sodium-glucose cotransporter 2 inhibitors demonstrate renoprotective effects in clinical trials.
• Glucagon-like peptide 1 receptor agonists and mineralocorticoid receptor antagonists show efficacy in DKD.
• Bardoxolone methyl improved glomerular filtration rate in the TSUBAKI trial; other agents targeting oxidative stress, inflammation, and renal hemodynamics are under investigation.

Conclusions:

• New therapeutic agents targeting oxidative stress, inflammation, hypoxia, and epigenetics offer potential for DKD treatment.
• Agents like hypoxia-inducible factor prolyl hydroxylase inhibitors and advanced glycation end-product inhibitors show promise in preclinical studies.
• Continued research into novel targets and therapies is crucial for developing effective treatments to overcome diabetic kidney disease.